FDA Approves First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease
The FDA has approved Ryoncil (remestemcel-L-rknd), the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients aged two months and older. This approval is a monumental milestone for regenerative medicine, offering a critical treatment option for a condition with limited alternatives and setting the stage [...]










